Brokerage Highlights Strong Earnings Momentum, Attractive Valuations and Long-Term Growth Drivers Across Banking and Healthcare Sectors

Kotak Securities has reiterated its bullish outlook on DCB Bank and Dr Lal PathLabs, identifying both companies as high-conviction investment ideas backed by improving fundamentals, robust earnings growth and favourable long-term sector trends. The brokerage believes the two stocks are well positioned to outperform over the medium term, supported by healthy business momentum, disciplined execution and attractive valuations.

While DCB Bank is benefiting from rapid expansion in secured retail lending and improving profitability, Dr Lal PathLabs continues to capitalise on India's growing demand for organised diagnostics and preventive healthcare services. According to Kotak Securities, both companies combine earnings visibility with resilient business models, making them attractive opportunities for long-term investors.

DCB Bank: Secured Lending Strategy Continues to Deliver

Recommendation: BUY
Current Market Price (CMP): ₹191
Fair Value (Target): ₹225

Technical Levels

• Resistance: ₹199 / ₹205

• Support: ₹188 / ₹185

DCB Bank has steadily strengthened its position as a niche private sector lender by focusing on secured lending across retail, MSME and agriculture segments. The bank has deliberately reduced dependence on riskier unsecured lending while expanding its presence in businesses that offer better asset quality and stable returns.

Its loan portfolio remains well diversified, reducing concentration risks while supporting sustainable growth.

Loan Book Composition

The bank's advances are distributed across multiple business segments:

• Mortgages – 39%

• Agriculture – 24%

• Corporate Lending – 8%

• MSME & SME Loans – 8%

• Other Retail Loans, including Gold Loans

This diversified lending mix provides greater resilience during economic cycles while supporting consistent earnings growth.

Pan-India Expansion Strengthens Franchise

Kotak Securities highlighted DCB Bank's expanding geographical footprint as another key positive.

The lender has established a strong presence across western and southern India while gradually expanding into underpenetrated markets in other regions.

Management continues to adopt a disciplined expansion strategy, focusing on markets that offer attractive opportunities without compromising credit quality.

The broadening distribution network is expected to support sustained customer acquisition and loan growth over the coming years.

Q1 FY27 Earnings Reinforce Growth Story

DCB Bank reported another strong quarterly performance, reinforcing confidence in its long-term business strategy.

Key Highlights

• Net Profit Growth: 35% Year-on-Year

• Loan Growth: 17% Year-on-Year

• Net Interest Margin (NIM): 3.4%

• Gross NPA: 2.4%

• Net NPA: 0.8%

The improvement in profitability was driven primarily by lower credit costs while maintaining healthy loan growth and stable margins.

Despite temporary pressure from higher gold loan slippages, asset quality remained well under control.

Management expects to maintain:

• Gross NPA below 2.5%

• Net NPA below 1%

through conservative underwriting standards and adequate provisioning.

Gold Loan Business Emerging as a Major Growth Engine

One of the standout performers within DCB Bank's portfolio has been its gold loan business.

Gold loan advances surged by an impressive 125% year-on-year, reflecting both strong customer demand and management's strategic focus on secured lending.

Gold loans offer several advantages:

• Lower credit risk

• Better collateral coverage

• Faster loan processing

• Attractive yields

• Stable asset quality

Alongside gold loans, mortgage lending continues to perform well, while structural changes in the MSME business are expected to revive growth over the medium term.

Kotak Securities projects:

• Loan CAGR of around 19–20%

• Deposit CAGR of nearly 19–20%

between FY26 and FY29.

Valuation Remains Attractive Despite Improving Fundamentals

Although operational performance has improved significantly, DCB Bank continues to trade at attractive valuations.

According to Kotak Securities:

• Valuation stands at approximately 0.9x FY27 Estimated Price-to-Book Value (P/BV)

The brokerage expects profitability to continue improving:

Earnings are expected to grow at nearly 20% CAGR, providing scope for valuation re-rating over the next few years.

Dr Lal PathLabs: Beneficiary of India's Expanding Healthcare Market

Recommendation: BUY
Current Market Price (CMP): ₹1,820
Fair Value (Target): ₹2,030

Technical Levels

• Resistance: ₹1,860 / ₹1,920

• Support: ₹1,780 / ₹1,720

Dr Lal PathLabs remains one of India's most recognised diagnostic healthcare companies with a legacy spanning more than seven decades.

The company has built one of the country's largest diagnostic networks through continuous investment in technology, laboratory infrastructure and quality standards.

Extensive Nationwide Diagnostic Network

The company's scale continues to provide a major competitive advantage.

Today, Dr Lal PathLabs operates:

• More than 300 laboratories

• Around 7,700 Patient Service Centres

• Nearly 14,000 collection points

• More than 4,800 diagnostic tests and preventive healthcare packages

Its broad geographic reach allows the company to serve both metropolitan cities and smaller towns, helping it capture growing healthcare demand across India.

Strongest Revenue Growth in Nearly Five Years

Kotak Securities noted that Dr Lal PathLabs delivered one of its strongest quarterly performances in recent years.

Q1 FY27 Performance Highlights

• Revenue Growth: 19% Year-on-Year

• Higher Patient Volumes

• Increase in Sample Collections

• Improved Realisations

• Margin Expansion

Revenue growth was driven by higher testing volumes, better pricing under government healthcare schemes such as CGHS and ECHS, and an increasing contribution from specialised diagnostic services.

Specialised tests including:

• Molecular Diagnostics

• Genetics

• Oncology

• Preventive Health Packages

continue to contribute a larger share of revenues while improving profitability.

Preventive Healthcare Continues to Drive Long-Term Growth

India's healthcare sector is witnessing structural changes that continue to benefit organised diagnostic companies.

Key industry trends include:

• Rising health awareness

• Increasing prevalence of lifestyle diseases

• Ageing population

• Higher healthcare spending

• Shift towards preventive healthcare

• Migration from unorganised laboratories to branded diagnostic chains

Dr Lal PathLabs is well positioned to benefit from these long-term trends.

The company's rural outreach programme continues to expand its presence in Tier-II and Tier-III cities, while Suburban Diagnostics has strengthened operations in western India.

International Expansion Opens New Growth Opportunities

The company has also begun expanding internationally.

A wholly owned subsidiary has been incorporated in Dubai, marking the first step in its overseas expansion strategy.

Management has indicated that it will continue exploring selective international opportunities while maintaining its primary focus on the domestic market.

This diversification could provide an additional long-term growth avenue.

Strong Financial Position Supports Future Expansion

One of the biggest strengths of Dr Lal PathLabs is its robust balance sheet.

The company continues to maintain:

• Debt-Free Status

• Strong Operating Cash Flow

• High Return Ratios

• Healthy Profit Margins

• Consistent Dividend Track Record

The healthy financial position enables continued investment in technology, laboratory expansion and specialised testing without increasing financial leverage.

Management expects to deliver mid-teen revenue growth during FY27.

Key Investment Positives

DCB Bank

Strengths

• Rapid growth in secured lending

• Improving asset quality

• Strong earnings momentum

• Attractive valuation

• Healthy return ratios

• Expanding gold loan franchise

Risks

• Slower credit growth

• Higher competitive intensity

• Interest rate fluctuations

• Gold loan portfolio volatility

Dr Lal PathLabs

Strengths

• Industry-leading diagnostic brand

• Extensive nationwide network

• Growing preventive healthcare demand

• Strong cash generation

• Debt-free balance sheet

• Expanding specialised diagnostics

Risks

• Increasing competition from online diagnostic platforms

• Pricing pressure

• Regulatory changes

• Execution risks in overseas expansion

Why Kotak Securities Remains Positive

According to the brokerage, both companies are operating in sectors with favourable structural growth drivers while maintaining disciplined execution.

DCB Bank offers exposure to India's expanding credit market through a high-quality secured lending portfolio, while Dr Lal PathLabs provides an opportunity to participate in the long-term growth of India's organised healthcare and diagnostics industry.

Both businesses also benefit from improving operational efficiency, healthy balance sheets and strong management execution.

Market Outlook

Kotak Securities believes DCB Bank and Dr Lal PathLabs remain well positioned to deliver sustainable earnings growth over the next few years. DCB Bank's secured lending strategy, strong deposit franchise and improving return ratios provide a solid foundation for long-term value creation, while Dr Lal PathLabs continues to benefit from rising demand for preventive healthcare, expanding diagnostic services and a trusted nationwide brand.

Although near-term market volatility may influence stock performance, the brokerage sees both companies as fundamentally strong businesses with attractive growth prospects and reasonable valuations. Investors seeking exposure to the financial and healthcare sectors may find these stocks well placed to benefit from India's long-term economic and demographic growth trends.